Pengaruh Vaksin BCG dalam Meningkatkan Proses Segresi Seluler pada Lesi Prakanker Serviks Uteri Derajat Rendah

Yudi Mulyana Hidayat, Putu Giri Saputro, Dodi Suardi, Gatot N. A. Winarno, Siti Salima, Ali Budi Harsono


Abstract


Tujuan: Penelitian ini adalah untuk menganalisis peranan pemberian vaksin bacille calmette-guerin (BCG) terhadap proses regresi seluler pada lesi prakanker serviks uteri derajat rendah
Metode: Penelitian ini merupakan penelitian eksperimental dengan rancangan pretest (IVA dan Histopatologi) - posttest (IVA dan Test HPV DNA) with control design di Poliklinik Rumah Sakit Dr. Hasan Sadikin Bandung pada bulan Desember 2017-Maret 2018.
Hasil: Untuk pemeriksaan IVA bulan ke-0 pada kelompok BCG kategori positif sebanyak 9 (100.0%) sedangkan untuk pemeriksaan IVA bulan ke-3 pada kelompok BCG kategori positif sebanyak 3 (33.3%) dan negatif menjadi sebanyak 6 (66.7%), pemeriksaan tes HPV DNA bulan ke 12 pada kelompok BCG kategori positif HPV DNA High Risk tidak ditemukan ( 0 % ). Hasil uji statistik pada kelompok perlakuan diperoleh nilai p<0.05. Untuk pemeriksaan IVA bulan ke-0 pada kelompok plasebo kategori positif sebanyak 9 (100.0%) sedangkan untuk pemeriksaan IVA bulan ke-3 pada kelompok plasebo kategori positif sebanyak 8 (88.9%) dan negatif menjadi sebanyak 1 (11.1%). pemeriksaan tes HPV DNA bulan ke 12 kelompok BCG kategori positif HPV DNA High Risk sebanyak  1 orang ( 11,1%). Hasil uji statistik pada kelompok kontrol diperoleh informasi nilai p>0.05.
Kesimpulan: Terdapat peranan pemberian vaksin BCG terhadap regresi seluler lesi prakanker serviks derajat rendah.

The effect of Bacille Calmette-Guerin vaccine on regression of cervical intraepithelial neoplasia-1

Abstract
Objective: The aim of this study was to analyze the role of Baccile Calmete Guerin (BCG) vaccines delivery in low grade precancerous cervical lesions.
Methods: The design of the study was a pretest and posttest experimental with control, done at Hasan Sadikin Hospital Bandung Outpatient Clinic during December 2017–March 2018.
Result: Patients with positive VIA test in the intervention group in month-0 were 9 patients (100.0%), in month-3 were 3 patients (33.33%) and the other 6 patients (66.7%) changed into negative. Patients with positive VIA test in the control group in month-0 were 9 patients (100.0%), in month 3 were 8 patients (88.9%) and the other 1 patients (11.1%) changed into negative. The result of statistical analysis in the intervention group was p<0.05. The result of statistical analysis in the control group was p>0.05.
Conclusion: : there is a role of BCG vaccine in low grade precancerous cervical lesions.

Key words: BCG vaccine, VIA test, Low grade cervical precancerous lesions.


Keywords


Vaksin BCG, pemeriksaan IVA, tes HPV DNA, lesi prakanker serviks derajat rendah.

Full Text:

PDF

References


yothi HR. Risk of malignancy index in assessment of pelvic mass. International Journal of Biomedical Research. IJBR (2014) 05 (03). 184-6.

Sinaga, FIK. Perbandigan Modifikasi Risk Of Malignancy Index (RMI) Dibanding Dengan RMI Dan Risk Of Ovarian Malignancy Algorythrm (ROMA) Dalam Prediksi Kanker Ovarium Tipe Epitel. 2016.

Karimi ZM, Mojaver SP, et al. Diagnostic Value of the Risk of Malignancy Index (RMI) for Detection of Pelvic Malignancies Compared with Pathology. Electron Physician.

;7(7):1505-10. Published 2015 Nov 20. doi:10.19082/1505.

Shia S. Initial Evaluation and Referral Guidelines for Management of Pelvic/Ovarian Masses. JOINT SOGC/GOC/SCC. Clinical Practice Guideline. No. 230, July 2009.

Rujuta J. Risk of Malignancy Index (RMI) in Evaluation of Adnexal Mass. J Obstet Gynaecol India. 2015 Apr; 65(2): 117–121.

Ghazali MV, Sastromiharjo S, Soedjarwo SR, Soelaryo T, Pramulyo HS. Studi Cros-sectional. Dasar-dasar Metodologi Penelitian Klinis. Jakarta. Ed 4. 2011. 130−144.

Kim HY. Statistical notes for clinical researchers: Chi-squared test and Fisher’s exact test. Restor Dent Endod. 2017;42(2):152-155.

Anton C, Carvalho FM, Oliveira EI, Maciel GA, Baracat EC, Carvalho JP. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics (Sao Paulo). 2012;67(5):437−441.

Dora SK, Dandapat AB, Pande B, Hota JP. A prospective study to evaluate the risk malignancy index and its diagnostic implication in patients with suspected ovarian mass. J Ovarian Res. 2017;10(1):55.

Aziz AB, Najmi N. Is Risk Malignancy Index a Useful Tool for Predicting Malignant Ovarian Masses in Developing Countries?. Obstet Gynecol Int. 2015;2015:951256.




DOI: http://dx.doi.org/10.24198/obgynia.v3i2.82

Refbacks

  • There are currently no refbacks.




     
     
Creative Commons License
Indonesian Journal of Obstetrics & Gynecology Science is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. 
  Web Analytics
  View My Stat